These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 6843667)

  • 1. Gene deletions in patients with haemophilia B and anti-factor IX antibodies.
    Giannelli F; Choo KH; Rees DJ; Boyd Y; Rizza CR; Brownlee GG
    Nature; 1983 May 12-18; 303(5913):181-2. PubMed ID: 6843667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular studies of haemophilia B in Sweden. Identification of patients with total deletion of the factor IX gene and without inhibitory antibodies.
    Wadelius C; Blombäck M; Pettersson U
    Hum Genet; 1988 Dec; 81(1):13-7. PubMed ID: 2848757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA analysis of seven patients with hemophilia B who have anti-factor IX antibodies: relationship to clinical manifestations and evidence that the abnormal gene was inherited.
    Tanimoto M; Kojima T; Kamiya T; Takamatsu J; Ogata K; Obata Y; Inagaki M; Iizuka A; Nagao T; Kurachi K
    J Lab Clin Med; 1988 Sep; 112(3):307-13. PubMed ID: 3411192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with hemophilia B (Christmas disease) who have anti-factor IX: genetic heterogeneity.
    Poon MC
    J Lab Clin Med; 1988 Sep; 112(3):283-4. PubMed ID: 3411190
    [No Abstract]   [Full Text] [Related]  

  • 5. Nullisomic deletion of the mcf.2 transforming gene in two haemophilia B patients.
    Anson DS; Blake DJ; Winship PR; Birnbaum D; Brownlee GG
    EMBO J; 1988 Sep; 7(9):2795-9. PubMed ID: 2846283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemophilia B with inhibitor: molecular analysis of the subtotal deletion of the factor IX gene.
    Hassan HJ; Leonardi A; Guerriero R; Chelucci C; Cianetti L; Ciavarella N; Ranieri P; Pilolli D; Peschle C
    Blood; 1985 Sep; 66(3):728-30. PubMed ID: 2992643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of carriers of haemophilia B.
    Orstavik KH; Veltkamp JJ; Bertina RM; Hermans J
    Br J Haematol; 1979 Jun; 42(2):293-301. PubMed ID: 465373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular diagnosis of inherited coagulation disorders--sequence analysis of hemophilia B patients with anti-factor IX antibodies].
    Tanimoto M; Matsushita T; Takamatsu J; Saito H
    Rinsho Byori; 1990 Sep; 38(9):1041-6. PubMed ID: 2232265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitive solid phase enzyme immunoassay for factor IX antigen and classification of hemophilia B.
    Takamatsu J; Kamiya T; Ogata K; Sugihara T; Koie K; Kato K
    Haemostasis; 1983; 13(1):9-16. PubMed ID: 6341181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intragenic Factor IX restriction site polymorphism in hemophilia B variants.
    Hassan HJ; Orlando M; Leonardi A; Chelucci C; Guerriero R; Mannucci PM; Mariani G; Peschle C
    Blood; 1985 Feb; 65(2):441-3. PubMed ID: 2981590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunologic studies of factor IX (Christmas factor). II. Immunoradiometric assay of factor IX antigen.
    Yang HC
    Br J Haematol; 1978 Jun; 39(2):215-24. PubMed ID: 678474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk.
    Thorland EC; Drost JB; Lusher JM; Warrier I; Shapiro A; Koerper MA; Dimichele D; Westman J; Key NS; Sommer SS
    Haemophilia; 1999 Mar; 5(2):101-5. PubMed ID: 10215957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of heterogeneity of haemophilia B for the detection of carriers.
    Panicucci F; Sagripanti A; Conte B; Pinori E; Vispi M; Lecchini L
    Haemostasis; 1980; 9(5):310-8. PubMed ID: 6157611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epitope mapping of human factor IX inhibitor antibodies.
    Takahashi I; Mizumo S; Kamiya T; Takamatsu J; Saito H
    Br J Haematol; 1994 Sep; 88(1):166-73. PubMed ID: 7528527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failure of immunosuppression in a severe haemophilia B patient with specific antibody.
    Allain JP; Frommel D
    Thromb Haemost; 1976 Aug; 36(1):86-9. PubMed ID: 1036830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anaphylactoid reactions and nephrotic syndrome--a considerable risk during factor IX treatment in patients with haemophilia B and inhibitors: a report on the outcome in two brothers.
    Tengborn L; Hansson S; Fasth A; Lübeck PO; Berg A; Ljung R
    Haemophilia; 1998 Nov; 4(6):854-9. PubMed ID: 10028310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological heterogeneity of haemophilia B: a multicentre study of 98 kindreds.
    Parekh VR; Mannucci PM; Ruggeri ZM
    Br J Haematol; 1978 Dec; 40(4):643-55. PubMed ID: 103564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spontaneous disappearance of an IgA anti-factor IX inhibitor in a child with Christmas disease.
    Carroll RR; Panush RS; Kitchens CS
    Am J Hematol; 1984 Oct; 17(3):321-5. PubMed ID: 6475941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate.
    Parquet A; Laurian Y; Rothschild C; Navarro R; Guérois C; Gay V; Durin A; Peynet J; Sultan Y
    Thromb Haemost; 1999 Oct; 82(4):1247-9. PubMed ID: 10544907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.
    Fields PA; Arruda VR; Armstrong E; Chu K; Mingozzi F; Hagstrom JN; Herzog RW; High KA
    Mol Ther; 2001 Sep; 4(3):201-10. PubMed ID: 11545610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.